The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis

Published: October 2017
No. of Pages: 104
Single User License: US $ 4000
Corporate User License: US $ 12000

The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.

The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.

Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market.  However the emergence of the IL-17 inhibitor class driven by Novartis’ Cosentyx and Eli Lilly’s Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.

The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-α inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen’s Remicade, and Amgen’s Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.

Stelara has been an important growth driver of Janssen’s immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.

Companies Mentioned

  • AbbVie
  • AbGenomics
  • AET Biotech
  • Amgen
  • Aprogen
  • AstraZeneca
  • Biocad
  • Biocon
  • Biogen
  • Biotest
  • BioXpress
  • BoehringerIngelheim
  • Celgene
  • Celltrion
  • Coherus Biosciences
  • Daiichi Sankyo
  • Dermira
  • Eli Lilly
  • EMD Serono
  • GlaxoSmithKline
  • Harvest Moon
  • Idera pharmaceuticals
  • Janssen (J&J)
  • Kyowa hakko Kirin
  • LG Chem
  • MabTech
  • mAbxience
  • Merck
  • Mochida
  • Momenta
  • Mycenax Biotech
  • Mylan
  • Nichiiko
  • Nippon Kayaku
  • Novartis
  • Oncobiologics
  • Pfizer
  • ProtalixBiotherapeutics
  • Samsung Bioepis
  • Sorrento Therapeutics
  • Sun Pharma
  • Takeda
  • TheraMAB
  • TSH Biopharm Corp
  • UCB

Published By: MP Advisors
Product Code: MP Advisors46

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy